Session Abstract – PMWC 2022 Silicon Valley

 Session Chair Profile

M.D., Professor of Medicine, Stanford University

Biography
Latha Palaniappan, MD, MS is Professor of Medicine and Scientific Director of Precision Genomics and Pharmacogenomics in Primary Care at Stanford. She is the faculty lead for the Stanford Biobank, a population based biobank designed to accelerate genetic and other -omics discovery.


 Speaker Profile

Ph.D., Sr Director, Global Market Access Strategy & HEOR, Illumina

Biography
Brock Schroeder is Senior Director of Global Market Access Strategy & HEOR at Illumina, where he leads efforts to generate evidence of clinical and economic utility of current and emerging clinical applications of NGS to support HTA, payer coverage, and patient access to clinical genomic tools. Prior to joining Illumina in 2017, Brock led Medical Affairs at Biotheranostics. Brock’s industry experience includes multiple therapeutic areas, including oncology, rare diseases, and reproductive health. Brock has authored >25 peer-reviewed manuscripts and >50 scientific congress abstracts. He received his BA in Biology from Washington University, and his PhD in Neuroscience from University of Wisconsin-Madison.


 Speaker Profile

PharmD, MPH, VP, Commercial Markets, Tempus

Biography
Mina Alsaraf Allo currently serves as Vice President, Business Development – Commercial Markets at Tempus Labs. Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. There, she focuses on creating partnerships with commercial payers and population health decision makers to drive access and value for the portfolio of assays, including next generation comprehensive genomic profiling and pharmacogenetics testing, and leveraging the combined clinical and molecular data to drive outcomes and economic utility. Her career spans a variety of managed care and biopharmaceutical access, value and health economics and outcomes research (HEOR) related roles, with a passion for ensuring equitable access along the patient journey towards innovative therapeutics and testing options.


 Speaker Profile

Ph.D., M.P.H., VP Health Economics and Outcomes Research, Optum Genomics

Biography
Stacey DaCosta Byfield currently leads the Genomics Health Economics and Outcomes Research (HEOR) Team focused on conducting observational research studies using administrative claims, EHR/medical record data and other data sources, including laboratory results data.  Stacey joined UnitedHealth Group (UHG) in 2009 in the OptumInsight Life Sciences HEOR group where she started as a Senior Researcher focusing on oncology studies.  She later served as VP, Research of the Life Sciences HEOR group before moving to OptumLabs were she led the Data Scientist team and most recently the Oncology Focus Area Research Team. Prior to joining UHG, she worked in the Department of Drug Use Policy and Pharmacoeconomics at the University of Texas M.D. Anderson Cancer Center as a Pharmacoeconomics Research Specialist. In this capacity, her main responsibilities included developing research designs to evaluate clinical, economic and humanistic outcomes of pharmaceutical products and services. She holds a PhD in Tumor Biology from Georgetown University and completed a basic science fellowship at the National Cancer Institute where her work focused on identifying targets of pharmaceutical intervention for metastatic breast cancer. Stacey also received her MPH with a concentration in clinical effectiveness from the Harvard T. H. Chan School of Public Health and has completed the Program in Cancer Outcomes Research Training (PCORT) Fellowship, a jointly sponsored program by the Massachusetts General Hospital and the Dana-Farber Harvard Cancer Center in Boston, Massachusetts.